Pharmacokinetics of the low molecular weight heparin dalteparin in cats

详细信息	查看全文 | 推荐本文 |

• 作者：Reinhard Mischke^a ; ^{Reinhard.Mischke@tiho-hannover.de} ; Judith Schmitt^a ; Sonja Wolken^b ; Claudia Bö ; hm^b ; Petra Wolf^c ; Manfred Kietzmann^d
• 关键词：Pharmacokinetics ; Anti-FXa activity ; Half-life ; Invasion ; Elimination ; Dalteparin ; Cat
• 刊名：The Veterinary Journal
• 出版年：2012
• 期刊代码：338_10900233
• 类别：med
• 出版时间：June, 2012
• 卷：192
• 期：3
• 页码：299-303
• 文件大小：283 K

摘要

Low molecular weight heparin (LMWH) is used as an anticoagulant in cats although only limited pharmacokinetic data are available in this species. The aim of the present study was to establish the pharmacokinetics of dalteparin in cats based on anti-FXa heparin activities. Groups of clinically healthy cats (six animals per treatment) received individual LMWH injections at three different doses intravenously (IV) (25, 50, 100 anti-factor Xa international units [IU anti-FXa]/kg) or subcutaneously (SC) (50, 100, 200 IU anti-FXa/kg). Blood samples were collected before and at various times after injection. Anti-FXa activity was measured with a chromogenic substrate test.

Following IV injection, maximum plasma heparin activities (C_max) were 0.67 卤 0.14, 1.44 卤 0.22 and 2.87 卤 0.38 IU anti-FXa/mL, respectively. The calculated mean half-life (t_陆) was between 39 and 57 min and was not significantly dose-dependent (P = 0.139). The volume of distribution (35-39 mL/kg) was almost equivalent to the plasma volume. After SC injection, C_max values of 0.41 卤 0.10, 0.86 卤 0.17 or 1.91 卤 0.16 IU anti-FXa/mL, respectively, were calculated at 91-110 min post-injection. The t_陆 values were between 106 and 122 min and were not significantly influenced by dose (P = 0.784). The bioavailability after SC injection was approximately 100%.

The high bioavailability of the SC administered LMWH dalteparin in cats was consistent with other species and indicated predictable blood levels. However, the comparatively short t_陆 may indicate the necessity of multiple daily injections, which should be verified in clinical trials.